ALPN News and Press, Alpine Immune Sciences Inc. From 06/13/21

Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal , not only for Alzheimer's patients, but...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today Alpine is set to join the broad-market Russell 3000® Index at the conclusion of t...

Alpine to hold an ALPN-202 Investor Event on Friday, June 4 at 7:00pm EDT Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced present...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today made an oral presentation of preclinical data from the company’s ALPN-303 program at the E...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of industry veteran Zelanna Goldberg, M.D., M.A.S. as its Chief Medical...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Alpine Immune Sciences is a fundamental stock that is ideal for you to build a core long-term position. The company recently released preliminary NEON-1 data for the upcoming 2021 ASCO. Early clinical results of ALPN-202 demonstrated modest efficacy for all dosages. However, you c...

Alpine Immune Sciences (ALPN) recently disclosed it has filed for a mixed shelf offering of up to $150M.The filing does not necessarily indicate that a sale has begun, or will occur in the future.Alpine shares down 1.8% to $10.28. For further details see: Alpine Immune Sc...

After a rise of ~30.9% over the past four days, Alpine Immune Sciences ([[ALPN]] -14.4%) has lost more than a tenth in value today in apparent reaction to a regulatory submission announcing a common stock offering of ~7.7M shares by selling shareholders.The share offer also includes...

- Alpine to hold Investor Event on Friday, June 4 at 7:00pm ET - - Program abstracts are now live on the ASCO website - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer a...